IRAK inhibitor 2 is interleukin-1 receptor associated kinase inhibitor .

CA-4948 is a selective and potent IRAK4 inhibitor which can be used as a therapeutic agent for hematological cancers with dysregulated TLR/MYD88/IRAK4 signaling. CA-4948 exhibits favorable DMPK properties, oral bioavailability, and is well tolerated in mice. Furthermore, CA-4948 is previously shown to exhibit dose-dependent efficacy in ABC-DLBCL MYD88-L265P xenograft tumor models

IRAK4-IN-4 is an interleukin-1 receptor–associated kinase 4 (IRAK4) inhibitor with IC50 of 2.8 nM. IRAK4-IN-4 also inhibits cyclic GMP-AMP synthase (cGAS) with IC50 of 2.1 nM.

AZ1495 是一种弱碱性、口服活性有效的白细胞介素-1 受体相关激酶 4 (IRAK4) 抑制剂。AZ1495 对 IRAK4 和 IRAK1 具有良好的物理化学和激酶选择性，IC50 值分别为 0.005 μM 和 0.023 μM。

Jh-X-119-01 is a novel potent and selective interleukin-1 receptor-associated kinases 1 (IRAK1) inhibitor.

KT-474是一种强效、选择性、口服生物利用度良好的IRAK4降解剂。它通过靶向并促进IRAK4蛋白的降解，干预其在自身免疫疾病中的作用。KT-474展示了在治疗包括自身免疫疾病在内的各种疾病中的潜力。

CA-4948 is a selective and orally bioavailable IRAK4 Inhibitor. It exhibited desirable ADME and PK profiles including good oral bioavailability in mice, rat, and dog and showed >90% tumor growth inhibition in relevant tumor models with excellent correlation with in vivo PD modulation.

Zimlovisertib (PF-06650833)一种有效、选择性且口服可利用的白介素-1 受体相关激酶 4 (IRAK4) 抑制剂，IC50 为 0.2 nM，在 PBMC 测试中的 IC50 为 2.4 nM，研究领域包括类风湿性关节炎、狼疮和淋巴瘤。

IRAK-1-4 Inhibitor I is a IRAK-4 inhibitor with IC50 of 200 nM.

AS 2444697 is a potent and selective interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor with IC50 of 21 nM.

IRAK 抑制剂 1 是一种有效的 IRAK-4 抑制剂，IC50 为 216 nM，同时对 JNK-1 和 JNK-2 的抑制作用较弱，IC50 值分别为 3.801 μM 和 >10 μM。

JNJ-1013是一种有效的选择性IRAK1降解剂，其对IRAK1、IRAK4和VHL FP的IC50值分别为72 nM、443 nM和1071 nM。JNJ-1013诱导凋亡，增加裂解的PARP表达，同时降低IRAK1、p-IKBα和pSTAT3(Tyr705)的表达。

APY0201 是一种强效、高选择性的 ATP 竞争性 PIKfyve 抑制剂（IC50 = 5.2 nM），可阻断磷脂酰肌醇 3-磷酸（PtdIns3P）向 PtdIns(3,5)P2 的转化。同时，它抑制小分子 IL-12/23 的产生。